Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
T2 Biosystems, Inc. (TTOO)
USD0.00
+0.00 (+16.67%)
US OTC Healthcare Medical - Diagnostics & Research
Address
101 Hartwell Avenue 2421
Lexington, MA, US
Lexington, MA, US
CEO
Craig R. Jalbert
Website
t2biosystems.com
IPO
2014-08-07
CIK 1492674 ISIN US89853L3024
Description
T2 Biosystems, Inc. is an in vitro diagnostics company that develops and commercializes innovative diagnostic solutions for global markets. Its proprietary technology platform enables the rapid detection of pathogens, biomarkers, and other critical abnormalities directly from a wide array of unpurified patient specimens, including whole blood, plasma, serum, saliva, sputum, cerebrospinal fluid, and urine. The company's commercial offerings include the T2Dx Instrument, a compact bench-top system designed to run various diagnostic assays. Its current suite of diagnostic tests features T2Candida, a direct-from-blood test that rapidly identifies bloodstream infections leading to sepsis and candidemia; T2Bacteria, another direct-from-blood assay for detecting bacterial pathogens commonly associated with sepsis; T2Resistance, which targets and identifies genes conferring carbapenem resistance; and the T2SARS-CoV-2 panel, developed to detect the SARS-CoV-2 virus. In addition to its existing products, T2 Biosystems is actively advancing several diagnostic candidates. These include T2Biothreat, aimed at identifying biothreat pathogens; a comprehensive sepsis panel designed to detect bloodstream infections caused by both bacterial and Candida species, along with antibiotic resistance markers; T2Cauris, which offers direct detection of the emerging superbug Candida auris in patient skin, blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel specifically engineered for the T2Dx Instrument to identify the bacteria responsible for Lyme disease. T2 Biosystems has also established strategic partnerships, such as its collaboration with Canon U.S. Life Sciences, Inc., to jointly develop a diagnostic test panel for Lyme disease. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+16.67%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5.3K
Beta
7.87
Float Shares
15.86M
Free Float %
56.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -73.33% | +300.00% | -62.79% | -93.33% | -84.00% | -99.45% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Hold
Price Targets & DCF
Current price
0.00
Low
5.00
+714,185.7%
Consensus
5.00
+714,185.7%
Median
5.00
+714,185.7%
High
5.00
+714,185.7%
Ratings Trend (MoM)
60% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
5.00
+714,185.7%
|
Quality scores
Altman Z-Score
-55.57
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-67.8% Q3'24: +34.9% (vs Q3'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+98.4% ★ Q3'24: +83.5% (vs Q3'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-743.1% Q3'24: -315.0% (vs Q3'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-621.9% Q3'24: -491.0% (vs Q3'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-774.9% Q3'24: -756.9% (vs Q3'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+5,017.3% Q3'24: +299.6% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-1.13× Q3'24: -0.49× (vs Q3'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.81M
est: 3.00M (-6.2%)
|
4.08M
est: 4.55M (-10.4%)
|
4.67M
est: 4.26M (+9.6%)
|
10.50M
est: 11.37M (-7.7%)
|
8.34M
est: 8.63M (-3.4%)
|
18.13M
est: 18.28M (-0.8%)
|
28.06M
est: 27.53M (+1.9%)
|
22.31M
est: 22.20M (+0.5%)
|
7.19M
est: 7.16M (+0.4%)
|
10.55M
est.
|
23.13M
est.
|
33.30M
33.30M – 33.30M
+44.0% YoY
|
45.70M
45.70M – 45.70M
+37.2% YoY
|
60.40M
60.40M – 60.40M
+32.2% YoY
|
| EBITDA |
-41.86M
est: -44.01M (+4.9%)
|
-48.43M
est: -46.83M (-3.4%)
|
-50.58M
est: -4.26M (-1,088.4%)
|
-41.96M
est: -11.37M (-269.0%)
|
-48.30M
est: -45.01M (-7.3%)
|
-36.71M
est: -18.28M (-100.8%)
|
-41.13M
est: -37.41M (-9.9%)
|
-54.87M
est: -36.66M (-49.7%)
|
-43.88M
est: -7.16M (-512.4%)
|
-10.55M
est.
|
-23.13M
est.
|
-33.30M
-33.30M – -33.30M
-44.0% YoY
|
-45.70M
-45.70M – -45.70M
-37.2% YoY
|
-60.40M
-60.40M – -60.40M
-32.2% YoY
|
| EBIT |
-43.32M
est: -45.61M (+5.0%)
|
-50.71M
est: -49.20M (-3.1%)
|
-55.76M
est: -4.26M (-1,210.1%)
|
-44.47M
est: -11.37M (-291.1%)
|
-51.94M
est: -48.79M (-6.5%)
|
-39.87M
est: -18.28M (-118.0%)
|
-43.67M
est: -41.13M (-6.2%)
|
-55.92M
est: -40.24M (-39.0%)
|
-44.73M
est: -7.16M (-524.4%)
|
-10.55M
est.
|
-23.13M
est.
|
-33.30M
-33.30M – -33.30M
-44.0% YoY
|
-45.70M
-45.70M – -45.70M
-37.2% YoY
|
-60.40M
-60.40M – -60.40M
-32.2% YoY
|
| Net Income |
-45.29M
est: -47.62M (+4.9%)
|
-54.80M
est: -52.95M (-3.5%)
|
-62.43M
est: -24.27B (+99.7%)
|
-51.15M
est: -15.79B (+99.7%)
|
-59.01M
est: -55.34M (-6.6%)
|
-46.80M
est: -5.19B (+99.1%)
|
-49.24M
est: -45.81M (-7.5%)
|
-62.00M
est: -52.12M (-19.0%)
|
-50.08M
est: -17.57M (-185.1%)
|
-8.09M
est.
|
-3.11M
est.
|
-1.83M
-1.83M – -1.83M
+41.2% YoY
|
-1.20M
-1.20M – -1.20M
+34.3% YoY
|
-783.0K
-783.0K – -783.0K
+34.8% YoY
|
| SGA |
19.09M
est: 6.17M (+209.3%)
|
24.08M
est: 9.37M (+156.8%)
|
22.76M
est: 8.77M (+159.6%)
|
25.70M
est: 23.42M (+9.7%)
|
27.30M
est: 17.77M (+53.7%)
|
21.29M
est: 37.65M (-43.5%)
|
28.53M
est: 24.73M (+15.3%)
|
30.74M
est: 45.72M (-32.8%)
|
24.83M
est: 14.75M (+68.3%)
|
21.73M
est.
|
47.62M
est.
|
68.58M
68.58M – 68.58M
+44.0% YoY
|
94.11M
94.11M – 94.11M
+37.2% YoY
|
124.39M
124.39M – 124.39M
+32.2% YoY
|
| EPS |
-220.91
est: -11,185.71 (+98.0%)
|
-210.66
est: -10,285.71 (+98.0%)
|
-194.29
est: -9,298.74 (+97.9%)
|
-126.12
est: -6,050.00 (+97.9%)
|
-6,934.20
est: -6,400.00 (-8.3%)
|
-1,928.54
est: -1,988.10 (+3.0%)
|
-1,549.82
est: -1,623.13 (+4.5%)
|
-1,222.14
est: -1,236.00 (+1.1%)
|
-19.19
est: -6.73 (-185.1%)
|
-3.10
est.
|
-1.19
est.
|
-0.70
-0.70 – -0.70
+41.2% YoY
|
-0.46
-0.46 – -0.46
+34.3% YoY
|
-0.30
-0.30 – -0.30
+34.8% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-39.23M
OE per share TTM
-5.78
Owner's Yield
-274,082.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
78.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
1.00
Insider transactions (90d)
0
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CRG Partners III Parallel Fund “A” L.P. | 12.04M | 4.10% | — | 12.04M | — | 12.04M | PN | Delaware | 2023-07-13 | ↗ |
| 2 | CR Group L.P. | 4.10M | 46.68% | — | 4.10M | — | 11.00 | IA | — | 2024-04-19 | ↗ |
| 3 | Nathan D. Hukill | 4.10M | 46.68% | — | 4.10M | — | 11.00 | IN | — | 2024-04-19 | ↗ |
| 4 | GSA Capital Partners LLP | 3.80M | 15.20% | — | — | — | — | — | United Kingdom | 2023-06-30 | ↗ |
| 5 | CRG Partners III (Cayman) Lev AIV I L.P. | 1.98M | 22.56% | — | 1.98M | — | 11.00 | PN | — | 2024-04-19 | ↗ |
| 6 | Armistice Capital, LLC | 1.40M | 7.99% | — | 1.40M | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 7 | Steven Boyd | 1.40M | 7.99% | — | 1.40M | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 8 | JACOB SAFIER | 1.00M | 5.70% | — | — | 1.00M | — | IN | UNITED STATES | 2024-11-06 | ↗ |
| 9 | JSAF HOLDINGS, LLC | 1.00M | 5.70% | — | — | 1.00M | — | OO | UNITED STATES | 2024-11-06 | ↗ |
| 10 | CRG Partners III Parallel Fund “B” (Cayman) L.P. | 878.4K | 9.99% | — | 878.4K | — | 11.00 | PN | — | 2024-04-19 | ↗ |
| 11 | CRG Partners III L.P. | 682.0K | 7.76% | — | 682.0K | — | 11.00 | PN | — | 2024-04-19 | ↗ |
| 12 | CRG Partners III – Parallel Fund “A” L.P. | 424.7K | 4.83% | — | 424.7K | — | 11.00 | PN | — | 2024-04-19 | ↗ |
| 13 | NEW DIMENSIONS TRADING LTD. | 350.0K | 7.10% | — | — | 350.0K | — | OO | UNITED STATES | 2024-03-11 | ↗ |
| 14 | CRG Partners III (Cayman) Unlev AIV I L.P. | 136.4K | 1.55% | — | 136.4K | — | 11.00 | PN | — | 2024-04-19 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
1
+0 vs prev Q
New positions
1
Closed positions
1
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | — -101.0 (-100.0%) | — -199.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.25
Bullish
Ratio by volume
3.00
Bullish
Buys
9
Sells
4
Shares acquired
830.9K
Shares disposed
82.6K
Cash buys
—
Cash sales
—
Net activity
+748,273
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-04 | Toft Robin | Director | A-Award | A | Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2024-11-04 | Sprague John M | Officer | A-Award | A | Restricted Stock Units | 180,000 | 0.00 | — | 180,000 | D | ↗ |
| 2024-11-04 | Sperzel John J III | Director / Officer | A-Award | A | Restricted Stock Units | 490,000 | 0.00 | — | 490,000 | D | ↗ |
| 2024-11-04 | Saunders Ninfa | Director | A-Award | A | Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2024-11-04 | LIEBMAN SEYMOUR | Director | A-Award | A | Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2024-11-04 | Giffin Brett A. | Officer | A-Award | A | Restricted Stock Units | 180,000 | 0.00 | — | 180,000 | D | ↗ |
| 2024-11-04 | Gibbs Michael Terrence | Officer | A-Award | A | Restricted Stock Units | 190,000 | 0.00 | — | 190,000 | D | ↗ |
| 2024-11-04 | Elsbree David B | Director | A-Award | A | Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2024-11-04 | CUMMING JOHN W | Director | A-Award | A | Restricted Stock Units | 35,000 | 0.00 | — | 35,000 | D | ↗ |
| 2024-11-04 | Adams Laura Lee | Director | A-Award | A | Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2024-09-13 | Elsbree David B | Director | S-Sale | D | Common Stock | 55 | 2.42 | 133.10 | 23 | — | ↗ |
| 2024-05-09 | CR Group L.P. | 10% Owner | C-Conversion | A | Common Stock | 108,752 | 0.00 | — | 4,704,729 | — | ↗ |
| 2024-05-03 | CR Group L.P. | 10% Owner | A-Award | A | Common Stock | 403,608 | 0.00 | — | 828,324 | — | ↗ |
| 2024-04-12 | CR Group L.P. | 10% Owner | A-Award | A | Common Stock | 1,647,315 | 0.00 | — | 1,983,262 | — | ↗ |
| 2024-02-24 | Sprague John M | Officer | M-Exempt | A | Common Stock | 29 | 0.00 | — | 141 | — | ↗ |
| 2024-02-24 | Sperzel John J III | Director / Officer | M-Exempt | A | Common Stock | 67 | 0.00 | — | 400 | — | ↗ |
| 2024-02-24 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 29 | 0.00 | — | 135 | — | ↗ |
| 2024-02-20 | Sprague John M | Officer | A-Award | A | Restricted Stock Units | 40 | 0.00 | — | 40 | — | ↗ |
| 2024-02-20 | Sperzel John J III | Director / Officer | M-Exempt | D | Restricted Stock Units | 160 | 0.00 | — | 160 | — | ↗ |
| 2024-02-20 | Giffin Brett A. | Officer | A-Award | A | Restricted Stock Units | 13 | 0.00 | — | 13 | — | ↗ |
| 2024-02-20 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 40 | 0.00 | — | 106 | — | ↗ |
| 2024-02-14 | CR Group L.P. | 10% Owner | C-Conversion | A | Common Stock | 488,273 | 0.00 | — | 488,273 | — | ↗ |
| 2024-01-01 | Toft Robin | Director | A-Award | A | Restricted Stock Units | 6,369 | 0.00 | — | 6,369 | — | ↗ |
| 2023-11-08 | Giffin Brett A. | Officer | M-Exempt | A | Common Stock | 33 | 0.00 | — | 64 | — | ↗ |
| 2023-10-18 | Adams Laura Lee | Director | M-Exempt | A | Common Stock | 7 | 0.00 | — | 37 | — | ↗ |
| 2023-09-28 | CR Group L.P. | 10% Owner | S-Sale | D | Common Stock | 1,937,852 | 0.16 | 305.2K | 0 | — | ↗ |
| 2023-09-27 | CR Group L.P. | 10% Owner | S-Sale | D | Common Stock | 1,621,313 | 0.19 | 310.6K | 1,937,852 | — | ↗ |
| 2023-09-26 | CR Group L.P. | 10% Owner | S-Sale | D | Common Stock | 2,156,717 | 0.20 | 432.9K | 5,250,961 | — | ↗ |
| 2023-09-25 | CR Group L.P. | 10% Owner | S-Sale | D | Common Stock | 19,996 | 0.25 | 5.0K | 1,481,535 | — | ↗ |
| 2023-09-22 | CR Group L.P. | 10% Owner | S-Sale | D | Common Stock | 1,264,920 | 0.26 | 327.4K | 4,675,098 | — | ↗ |
| 2023-09-21 | CR Group L.P. | 10% Owner | S-Sale | D | Common Stock | 2,534,754 | 0.30 | 761.7K | 9,538,970 | — | ↗ |
| 2023-09-20 | CR Group L.P. | 10% Owner | S-Sale | D | Common Stock | 620,167 | 0.31 | 192.6K | 2,414,745 | — | ↗ |
| 2023-09-19 | CR Group L.P. | 10% Owner | S-Sale | D | Common Stock | 4,159,717 | 0.37 | 1.52M | 15,174,560 | — | ↗ |
| 2023-09-15 | Toft Robin | Director | M-Exempt | D | Restricted Stock Units | 2,300 | 0.00 | — | 0 | — | ↗ |
| 2023-09-15 | Saunders Ninfa | Director | M-Exempt | A | Common Stock | 2,300 | 0.00 | — | 7,322 | — | ↗ |
| 2023-09-15 | LIEBMAN SEYMOUR | Director | M-Exempt | A | Common Stock | 2,300 | 0.00 | — | 7,002 | — | ↗ |
| 2023-09-15 | Elsbree David B | Director | M-Exempt | D | Restricted Stock Units | 2,300 | 0.00 | — | 0 | — | ↗ |
| 2023-09-15 | CUMMING JOHN W | Director | M-Exempt | A | Common Stock | 2,600 | 0.00 | — | 5,256 | — | ↗ |
| 2023-09-15 | Bernard Thierry | Director | M-Exempt | D | Restricted Stock Units | 2,300 | 0.00 | — | 0 | — | ↗ |
| 2023-09-15 | Adams Laura Lee | Director | M-Exempt | A | Common Stock | 2,300 | 0.00 | — | 3,032 | — | ↗ |
| 2023-08-06 | Toft Robin | Director | M-Exempt | A | Common Stock | 454 | 0.00 | — | 3,472 | — | ↗ |
| 2023-08-06 | Saunders Ninfa | Director | M-Exempt | A | Common Stock | 454 | 0.00 | — | 5,022 | — | ↗ |
| 2023-08-06 | Bernard Thierry | Director | M-Exempt | A | Common Stock | 454 | 0.00 | — | 5,022 | — | ↗ |
| 2023-07-03 | CR Group L.P. | 10% Owner | A-Award | A | Common Stock | 13,105,006 | 0.00 | — | 13,105,006 | — | ↗ |
| 2023-03-28 | Gibbs Michael Terrence | Officer | S-Sale | D | Common Stock | 239 | 0.48 | 114.96 | 6,612 | — | ↗ |
| 2023-03-24 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 333 | 0.00 | — | 6,850 | — | ↗ |
| 2023-02-28 | Sprague John M | Officer | S-Sale | D | Common Stock | 1,148 | 0.59 | 677.32 | 7,268 | — | ↗ |
| 2023-02-28 | Sperzel John J III | Director / Officer | S-Sale | D | Common Stock | 2,898 | 0.59 | 1.7K | 17,329 | — | ↗ |
| 2023-02-28 | Gibbs Michael Terrence | Officer | S-Sale | D | Common Stock | 1,585 | 0.59 | 935.15 | 6,517 | — | ↗ |
| 2023-02-24 | Sprague John M | Officer | M-Exempt | A | Common Stock | 2,914 | 0.00 | — | 8,416 | — | ↗ |
| 2023-02-24 | Sperzel John J III | Director / Officer | M-Exempt | A | Common Stock | 6,667 | 0.00 | — | 20,227 | — | ↗ |
| 2023-02-24 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 2,914 | 0.00 | — | 8,102 | — | ↗ |
| 2023-02-22 | Sprague John M | Officer | S-Sale | D | Common Stock | 1,545 | 0.65 | 1.0K | 5,502 | — | ↗ |
| 2023-02-22 | Sperzel John J III | Director / Officer | S-Sale | D | Common Stock | 6,875 | 0.65 | 4.5K | 13,560 | — | ↗ |
| 2023-02-22 | Giffin Brett A. | Officer | S-Sale | D | Common Stock | 537 | 0.65 | 349.05 | 841 | D | ↗ |
| 2023-02-22 | Gibbs Michael Terrence | Officer | S-Sale | D | Common Stock | 2,145 | 0.65 | 1.4K | 5,188 | — | ↗ |
| 2023-02-20 | Sprague John M | Officer | M-Exempt | A | Common Stock | 4,000 | 0.00 | — | 7,047 | — | ↗ |
| 2023-02-20 | Sperzel John J III | Director / Officer | M-Exempt | A | Common Stock | 16,000 | 0.00 | — | 20,435 | — | ↗ |
| 2023-02-20 | Giffin Brett A. | Officer | M-Exempt | A | Common Stock | 1,333 | 0.00 | — | 1,378 | D | ↗ |
| 2023-02-20 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 4,000 | 0.00 | — | 7,333 | — | ↗ |
| 2023-01-01 | Saunders Ninfa | Director | M-Exempt | A | Common Stock | 1,550 | 0.00 | — | 4,568 | — | ↗ |
| 2023-01-01 | Bernard Thierry | Director | M-Exempt | A | Common Stock | 1,550 | 0.00 | — | 4,568 | — | ↗ |
| 2022-11-10 | Giffin Brett A. | Officer | S-Sale | D | Common Stock | 1,292 | 1.79 | 2.3K | 2,253 | — | ↗ |
| 2022-11-08 | Giffin Brett A. | Officer | M-Exempt | A | Common Stock | 3,333 | 0.00 | — | 3,545 | — | ↗ |
| 2022-10-18 | Adams Laura Lee | Director | M-Exempt | D | Restricted Stock Units | 732 | 0.00 | — | 1,464 | — | ↗ |
| 2022-10-11 | Toft Robin | Director | A-Award | A | Restricted Stock Units | 115,000 | 0.00 | — | 115,000 | — | ↗ |
| 2022-10-11 | Saunders Ninfa | Director | A-Award | A | Restricted Stock Units | 115,000 | 0.00 | — | 115,000 | — | ↗ |
| 2022-10-11 | LIEBMAN SEYMOUR | Director | A-Award | A | Restricted Stock Units | 115,000 | 0.00 | — | 115,000 | — | ↗ |
| 2022-10-11 | Elsbree David B | Director | A-Award | A | Restricted Stock Units | 115,000 | 0.00 | — | 115,000 | — | ↗ |
| 2022-10-11 | CUMMING JOHN W | Director | A-Award | A | Restricted Stock Units | 130,000 | 0.00 | — | 130,000 | — | ↗ |
| 2022-10-11 | Bernard Thierry | Director | A-Award | A | Restricted Stock Units | 115,000 | 0.00 | — | 115,000 | — | ↗ |
| 2022-10-11 | Adams Laura Lee | Director | A-Award | A | Restricted Stock Units | 115,000 | 0.00 | — | 115,000 | — | ↗ |
| 2022-08-06 | Toft Robin | Director | M-Exempt | D | Restricted Stock Units | 22,727 | 0.00 | — | 22,727 | — | ↗ |
| 2022-08-06 | Saunders Ninfa | Director | M-Exempt | A | Common Stock | 22,727 | 0.00 | — | 150,936 | — | ↗ |
| 2022-08-06 | Bernard Thierry | Director | M-Exempt | A | Common Stock | 22,727 | 0.00 | — | 150,936 | — | ↗ |
| 2022-06-25 | Toft Robin | Director | M-Exempt | A | Common Stock | 73,224 | 0.00 | — | 128,209 | — | ↗ |
| 2022-06-25 | Saunders Ninfa | Director | M-Exempt | D | Restricted Stock Units | 73,224 | 0.00 | — | 0 | — | ↗ |
| 2022-06-25 | LIEBMAN SEYMOUR | Director | M-Exempt | A | Common Stock | 73,224 | 0.00 | — | 235,121 | — | ↗ |
| 2022-06-25 | Elsbree David B | Director | M-Exempt | A | Common Stock | 73,224 | 0.00 | — | 276,205 | — | ↗ |
| 2022-06-25 | CUMMING JOHN W | Director | M-Exempt | A | Common Stock | 81,967 | 0.00 | — | 132,819 | — | ↗ |
| 2022-06-25 | Bernard Thierry | Director | M-Exempt | A | Common Stock | 73,224 | 0.00 | — | 128,209 | — | ↗ |
| 2022-04-08 | Sprague John M | Officer | P-Purchase | A | Common Stock | 10,000 | 0.48 | 4.8K | 152,350 | — | ↗ |
| 2022-04-08 | Giffin Brett A. | Officer | P-Purchase | A | Common Stock | 10,600 | 0.49 | 5.2K | 10,600 | — | ↗ |
| 2022-04-08 | Barclay Alec | Officer | P-Purchase | A | Common Stock | 12,952 | 0.50 | 6.5K | 181,945 | — | ↗ |
| 2022-04-07 | Sperzel John J III | Officer | P-Purchase | A | Common Stock | 30,000 | 0.50 | 15.0K | 221,773 | — | ↗ |
| 2022-04-07 | Gibbs Michael Terrence | Officer | P-Purchase | A | Common Stock | 10,000 | 0.49 | 4.9K | 166,651 | — | ↗ |
| 2022-03-24 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 16,666 | 0.00 | — | 165,441 | — | ↗ |
| 2022-03-14 | Barclay Alec | Officer | M-Exempt | A | Common Stock | 21,666 | 0.00 | — | 180,421 | — | ↗ |
| 2022-02-26 | Giffin Brett A. | Officer | A-Award | A | Restricted Stock Units | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2022-02-24 | Sprague John M | Officer | F-InKind | D | Common Stock | 55,008 | 0.45 | 24.7K | 136,196 | D | ↗ |
| 2022-02-24 | Sperzel John J III | Director / Officer | F-InKind | D | Common Stock | 141,560 | 0.45 | 63.5K | 191,773 | — | ↗ |
| 2022-02-24 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 145,719 | 0.00 | — | 225,642 | — | ↗ |
| 2022-02-24 | Barclay Alec | Officer | M-Exempt | D | Restricted Stock Units | 168,488 | 0.00 | — | 336,976 | — | ↗ |
| 2022-02-21 | Sprague John M | Officer | M-Exempt | D | Restricted Stock Units | 10,000 | 0.00 | — | 0 | D | ↗ |
| 2022-02-21 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 75,198 | D | ↗ |
| 2022-02-21 | Barclay Alec | Officer | M-Exempt | D | Restricted Stock Units | 10,000 | 0.00 | — | 0 | — | ↗ |
| 2022-02-20 | Sprague John M | Officer | A-Award | A | Restricted Stock Units | 600,000 | 0.00 | — | 600,000 | D | ↗ |
| 2022-02-20 | Sperzel John J III | Director / Officer | A-Award | A | Restricted Stock Units | 2,400,000 | 0.00 | — | 2,400,000 | — | ↗ |
| 2022-02-20 | Giffin Brett A. | Officer | A-Award | A | Restricted Stock Units | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-02-20 | Gibbs Michael Terrence | Officer | A-Award | A | Restricted Stock Units | 600,000 | 0.00 | — | 600,000 | D | ↗ |
| 2022-02-20 | Barclay Alec | Officer | A-Award | A | Restricted Stock Units | 600,000 | 0.00 | — | 600,000 | — | ↗ |
| 2022-02-20 | Ahuja Aparna | Officer | A-Award | A | Restricted Stock Units | 600,000 | 0.00 | — | 600,000 | — | ↗ |
| 2022-01-06 | Ahuja Aparna | Officer | S-Sale | D | Common Stock | 61,988 | 0.48 | 29.8K | 107,611 | — | ↗ |
| 2022-01-05 | Ahuja Aparna | Officer | M-Exempt | D | Restricted Stock Units | 153,664 | 0.00 | — | 307,328 | — | ↗ |
| 2022-01-01 | Toft Robin | Director | M-Exempt | A | Common Stock | 32,258 | 0.00 | — | 54,985 | — | ↗ |
| 2022-01-01 | Saunders Ninfa | Director | A-Award | A | Restricted Stock Units | 77,519 | 0.00 | — | 77,519 | — | ↗ |
| 2022-01-01 | LIEBMAN SEYMOUR | Director | M-Exempt | A | Restricted Stock Units | 32,258 | 0.00 | — | 0 | — | ↗ |
| 2022-01-01 | Elsbree David B | Director | M-Exempt | A | Common Stock | 32,258 | 0.00 | — | 202,981 | — | ↗ |
| 2022-01-01 | Bernard Thierry | Director | M-Exempt | A | Restricted Stock Units | 32,258 | 0.00 | — | 0 | — | ↗ |
| 2021-11-08 | Giffin Brett A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-18 | Adams Laura Lee | Director | — | D | Restricted Stock Units | 109,836 | 0.00 | — | 0 | — | ↗ |
| 2021-08-06 | Toft Robin | Director | M-Exempt | A | Common Stock | 22,727 | 0.00 | — | 22,727 | — | ↗ |
| 2021-08-06 | Saunders Ninfa | Director | M-Exempt | A | Common Stock | 22,727 | 0.00 | — | 22,727 | — | ↗ |
| 2021-08-06 | Bernard Thierry | Director | M-Exempt | A | Common Stock | 22,727 | 0.00 | — | 22,727 | — | ↗ |
| 2021-07-01 | McDonough John | Director | S-Sale | D | Common Stock | 18,182 | 1.16 | 21.1K | 516,386 | — | ↗ |
| 2021-07-01 | CUMMING JOHN W | Director | S-Sale | D | Common Stock | 18,182 | 1.16 | 21.1K | 50,852 | — | ↗ |
| 2021-06-25 | Toft Robin | Director | A-Award | A | Restricted Stock Units | 73,224 | 0.00 | — | 73,224 | — | ↗ |
| 2021-06-25 | Saunders Ninfa | Director | A-Award | A | Restricted Stock Units | 73,224 | 0.00 | — | 73,224 | — | ↗ |
| 2021-06-25 | McDonough John | Director | A-Award | A | Restricted Stock Units | 81,967 | 0.00 | — | 81,967 | — | ↗ |
| 2021-06-25 | LIEBMAN SEYMOUR | Director | A-Award | A | Restricted Stock Units | 73,224 | 0.00 | — | 73,224 | — | ↗ |
| 2021-06-25 | Elsbree David B | Director | M-Exempt | D | Restricted Stock Units | 45,454 | 0.00 | — | 45,454 | — | ↗ |
| 2021-06-25 | CUMMING JOHN W | Director | M-Exempt | D | Restricted Stock Units | 45,454 | 0.00 | — | 45,454 | — | ↗ |
| 2021-06-25 | Bernard Thierry | Director | A-Award | A | Restricted Stock Units | 73,224 | 0.00 | — | 73,224 | — | ↗ |
| 2021-03-25 | Gibbs Michael Terrence | Officer | S-Sale | D | Common Stock | 8,758 | 1.56 | 13.7K | 73,256 | — | ↗ |
| 2021-03-24 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 16,667 | 0.00 | — | 82,014 | — | ↗ |
| 2021-03-17 | Pare Anthony | Officer | S-Sale | D | Common Stock | 9,620 | 1.84 | 17.7K | 31,612 | — | ↗ |
| 2021-03-17 | Barclay Alec | Officer | S-Sale | D | Common Stock | 12,494 | 1.86 | 23.2K | 74,420 | — | ↗ |
| 2021-03-14 | Pare Anthony | Officer | M-Exempt | A | Common Stock | 17,500 | 0.00 | — | 41,232 | — | ↗ |
| 2021-03-14 | Barclay Alec | Officer | M-Exempt | A | Common Stock | 21,667 | 0.00 | — | 86,914 | — | ↗ |
| 2021-02-24 | Sprague John M | Officer | A-Award | A | Restricted Stock Units | 437,158 | 0.00 | — | 437,158 | — | ↗ |
| 2021-02-24 | Sperzel John J III | Director / Officer | A-Award | A | Restricted Stock Units | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2021-02-24 | Pare Anthony | Officer | A-Award | A | Restricted Stock Units | 505,464 | 0.00 | — | 505,464 | — | ↗ |
| 2021-02-24 | Gibbs Michael Terrence | Officer | A-Award | A | Restricted Stock Units | 437,158 | 0.00 | — | 437,158 | — | ↗ |
| 2021-02-24 | Barclay Alec | Officer | F-InKind | D | Common Stock | 88,878 | 0.45 | 39.9K | 158,755 | — | ↗ |
| 2021-02-23 | Sprague John M | Officer | S-Sale | D | Common Stock | 5,250 | 2.04 | 10.7K | 35,485 | — | ↗ |
| 2021-02-23 | Gibbs Michael Terrence | Officer | S-Sale | D | Common Stock | 7,280 | 2.06 | 15.0K | 65,347 | — | ↗ |
| 2021-02-23 | Barclay Alec | Officer | S-Sale | D | Common Stock | 7,280 | 2.06 | 15.0K | 65,247 | — | ↗ |
| 2021-02-21 | Sprague John M | Officer | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 40,735 | — | ↗ |
| 2021-02-21 | Gibbs Michael Terrence | Officer | M-Exempt | D | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-02-21 | Barclay Alec | Officer | M-Exempt | D | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-01-05 | Ahuja Aparna | Officer | A-Award | A | Restricted Stock Units | 460,992 | 0.00 | — | 460,992 | — | ↗ |
| 2021-01-01 | Toft Robin | Director | A-Award | A | Restricted Stock Units | 32,258 | 0.00 | — | 32,258 | — | ↗ |
| 2021-01-01 | Saunders Ninfa | Director | A-Award | A | Restricted Stock Units | 32,258 | 0.00 | — | 32,258 | — | ↗ |
| 2021-01-01 | LIEBMAN SEYMOUR | Director | M-Exempt | A | Common Stock | 34,188 | 0.00 | — | 84,185 | — | ↗ |
| 2021-01-01 | Elsbree David B | Director | M-Exempt | A | Common Stock | 34,188 | 0.00 | — | 125,269 | — | ↗ |
| 2021-01-01 | Bernard Thierry | Director | A-Award | A | Restricted Stock Units | 32,258 | 0.00 | — | 32,258 | — | ↗ |
| 2020-08-06 | Toft Robin | Director | A-Award | A | Restricted Stock Units | 68,181 | 0.00 | — | 68,181 | — | ↗ |
| 2020-08-06 | Saunders Ninfa | Director | A-Award | A | Restricted Stock Units | 68,181 | 0.00 | — | 68,181 | — | ↗ |
| 2020-08-06 | McDonough John | Director | A-Award | A | Restricted Stock Units | 45,454 | 0.00 | — | 45,454 | — | ↗ |
| 2020-08-06 | LIEBMAN SEYMOUR | Director | A-Award | A | Restricted Stock Units | 45,454 | 0.00 | — | 45,454 | — | ↗ |
| 2020-08-06 | Elsbree David B | Director | A-Award | A | Restricted Stock Units | 45,454 | 0.00 | — | 45,454 | — | ↗ |
| 2020-08-06 | CUMMING JOHN W | Director | A-Award | A | Restricted Stock Units | 45,454 | 0.00 | — | 45,454 | — | ↗ |
| 2020-08-06 | Bernard Thierry | Director | A-Award | A | Restricted Stock Units | 68,181 | 0.00 | — | 68,181 | — | ↗ |
| 2020-06-14 | Toft Robin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-14 | Saunders Ninfa | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-14 | Bernard Thierry | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-20 | Jones Adrian M | Director | P-Purchase | A | Common Stock | 5,126 | 0.80 | 4.1K | 4,201,582 | — | ↗ |
| 2020-05-20 | GOLDMAN SACHS & CO. LLC | 10% Owner | P-Purchase | A | Common Stock | 5,126 | 0.80 | 4.1K | 4,201,582 | — | ↗ |
| 2020-05-19 | Jones Adrian M | Director | P-Purchase | A | Common Stock | 10,328 | 0.83 | 8.6K | 4,199,287 | — | ↗ |
| 2020-05-19 | GOLDMAN SACHS & CO. LLC | 10% Owner | S-Sale | D | Common Stock | 3,235 | 0.83 | 2.7K | 4,193,021 | — | ↗ |
| 2020-05-12 | Jones Adrian M | Director | S-Sale | D | Common Stock | 2,500 | 0.55 | 1.4K | 4,196,456 | — | ↗ |
| 2020-05-12 | GOLDMAN SACHS & CO. LLC | 10% Owner | S-Sale | D | Common Stock | 2,500 | 0.55 | 1.4K | 4,196,456 | — | ↗ |
| 2020-05-06 | Jones Adrian M | Director | S-Sale | D | Common Stock | 100 | 0.53 | 53.25 | 4,190,651 | — | ↗ |
| 2020-05-06 | GOLDMAN SACHS & CO. LLC | 10% Owner | S-Sale | D | Common Stock | 2,655 | 0.52 | 1.4K | 4,193,801 | — | ↗ |
| 2020-04-09 | Jones Adrian M | Director | P-Purchase | A | Common Stock | 1,000 | 0.49 | 490.00 | 4,197,456 | — | ↗ |
| 2020-04-09 | GOLDMAN SACHS & CO. LLC | 10% Owner | S-Sale | D | Common Stock | 1,000 | 0.49 | 490.00 | 4,196,456 | — | ↗ |
| 2020-03-25 | Jones Adrian M | Director | P-Purchase | A | Common Stock | 600 | 0.93 | 556.74 | 4,197,056 | — | ↗ |
| 2020-03-25 | GOLDMAN SACHS & CO. LLC | 10% Owner | P-Purchase | A | Common Stock | 600 | 0.93 | 556.74 | 4,197,056 | — | ↗ |
| 2020-03-24 | Jones Adrian M | Director | S-Sale | D | Common Stock | 500 | 0.38 | 189.00 | 4,196,456 | — | ↗ |
| 2020-03-24 | Gibbs Michael Terrence | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.39 | 39.0K | 100,000 | — | ↗ |
| 2020-03-24 | GOLDMAN SACHS & CO. LLC | 10% Owner | P-Purchase | A | Common Stock | 500 | 0.38 | 189.00 | 4,196,956 | — | ↗ |
| 2020-03-14 | Pare Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 105,000 | 0.40 | 41.5K | 105,000 | — | ↗ |
| 2020-03-14 | Lowery Thomas J. | Officer | A-Award | A | Stock Option (Right to Buy) | 180,000 | 0.40 | 71.1K | 180,000 | — | ↗ |
| 2020-03-14 | Barclay Alec | Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 0.40 | 51.4K | 130,000 | — | ↗ |
| 2020-02-24 | Sprague John M | Officer | S-Sale | D | Common Stock | 4,166 | 0.82 | 3.4K | 22,222 | — | ↗ |
| 2020-02-24 | Lowery Thomas J. | Officer | S-Sale | D | Common Stock | 5,808 | 0.82 | 4.8K | 68,994 | — | ↗ |
| 2020-02-24 | Gibbs Michael Terrence | Officer | S-Sale | D | Common Stock | 5,808 | 0.82 | 4.8K | 60,779 | — | ↗ |
| 2020-02-24 | Barclay Alec | Officer | S-Sale | D | Common Stock | 5,808 | 0.82 | 4.8K | 46,294 | — | ↗ |
| 2020-02-21 | Sprague John M | Officer | M-Exempt | A | Restricted Stock Units | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2020-02-21 | Lowery Thomas J. | Officer | M-Exempt | A | Restricted Stock Units | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2020-02-21 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 66,587 | — | ↗ |
| 2020-02-21 | Barclay Alec | Officer | M-Exempt | A | Restricted Stock Units | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2020-02-11 | Lowery Thomas J. | Officer | S-Sale | D | Common Stock | 3,200 | 0.77 | 2.5K | 64,802 | — | ↗ |
| 2020-02-11 | Gibbs Michael Terrence | Officer | S-Sale | D | Common Stock | 3,200 | 0.77 | 2.5K | 56,587 | — | ↗ |
| 2020-02-09 | Lowery Thomas J. | Officer | M-Exempt | A | Common Stock | 5,833 | 0.00 | — | 68,002 | — | ↗ |
| 2020-02-09 | Gibbs Michael Terrence | Officer | M-Exempt | A | Common Stock | 5,833 | 0.00 | — | 59,787 | — | ↗ |
| 2020-02-03 | McDonough John | Director | S-Sale | D | Common Stock | 23,754 | 0.88 | 20.9K | 489,114 | — | ↗ |
| 2020-02-03 | Lowery Thomas J. | Officer | S-Sale | D | Common Stock | 7,535 | 0.88 | 6.6K | 62,169 | — | ↗ |
| 2020-02-03 | Gibbs Michael Terrence | Officer | S-Sale | D | Common Stock | 3,283 | 0.88 | 2.9K | 53,954 | — | ↗ |
| 2020-01-23 | McDonough John | Director | S-Sale | D | Common Stock | 57,417 | 1.15 | 66.0K | 512,868 | — | ↗ |
| 2020-01-13 | Pare Anthony | Officer | — | D | Common Stock | 0 | 0.00 | — | 4,577 | — | ↗ |
| 2020-01-08 | Sperzel John J III | Director / Officer | — | D | Stock Option | 3,000,000 | 1.15 | 3.45M | 0 | — | ↗ |
| 2020-01-08 | McDonough John | Director | M-Exempt | D | Restricted Stock Units | 100,000 | 0.00 | — | 0 | — | ↗ |
| 2020-01-03 | Elsbree David B | Director | S-Sale | D | Common Stock | 5,316 | 1.16 | 6.2K | 91,081 | — | ↗ |
| 2020-01-02 | Jones Adrian M | Director | A-Award | A | Common Stock | 34,188 | 0.00 | — | 4,270,641 | — | ↗ |
| 2020-01-02 | GOLDMAN SACHS GROUP INC | 10% Owner | A-Award | A | Common Stock | 34,188 | 0.00 | — | 4,270,641 | — | ↗ |
| 2020-01-01 | LIEBMAN SEYMOUR | Director | A-Award | A | Restricted Stock Units | 34,188 | 0.00 | — | 34,188 | — | ↗ |
| 2020-01-01 | Elsbree David B | Director | M-Exempt | A | Common Stock | 13,289 | 0.00 | — | 96,397 | — | ↗ |
| 2019-09-11 | Barclay Alec | Officer | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 46,312 | — | ↗ |
| 2019-09-10 | Sprague John M | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.43 | 71.5K | 50,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-4.0K
Shares Outstanding
28.05M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | John Sperzel, President, Chief Executive Officer and Chairman of the Board of Directors | 575.0K | — | — | — | 287.5K | 3.0K | 865.5K | 0.00% | ↗ |
| 2 | 2023 | Michael Gibbs, SVP and General Counsel | 387.5K | 80.0K | — | — | 152.1K | 3.0K | 622.6K | 0.00% | ↗ |
| 3 | 2023 | John Sprague, Chief Financial Officer | 382.5K | 80.0K | — | — | 115.5K | 3.0K | 581.0K | 0.00% | ↗ |
| 4 | 2022 | John Sperzel, President, Chief Executive Officer and Chairman of the Board of Directors | 575.0K | — | 1.12M | — | 287.5K | 3.0K | 1.99M | 56.41% | ↗ |
| 5 | 2022 | Michael Gibbs, SVP and General Counsel | 371.8K | — | 280.0K | — | 112.5K | 3.0K | 767.3K | 36.49% | ↗ |
| 6 | 2022 | John Sprague, Chief Financial Officer | 368.3K | — | 280.0K | — | 111.0K | 3.0K | 762.3K | 36.73% | ↗ |
| 7 | 2021 | John Sperzel, President, Chief Executive Officer and Chairman of the Board of Directors | 562.5K | — | 2.48M | — | 460.0K | 3.0K | 3.51M | 70.75% | ↗ |
| 8 | 2021 | Alec Barclay, SVP and Chief Operations Officer | 356.7K | — | 1.25M | — | 183.6K | 4.2K | 1.80M | 69.72% | ↗ |
| 9 | 2021 | Michael Gibbs, SVP and General Counsel | 353.3K | — | 1.08M | — | 170.9K | 3.0K | 1.61M | 67.28% | ↗ |
| 10 | 2020 | John Sperzel, President, Chief Executive Officer and Chairman of the Board of Directors | 490.7K | — | — | 2.57M | 393.8K | 3.0K | 3.46M | 74.34% | ↗ |
| 11 | 2020 | John Sperzel, President and Chief Executive Officer | 490.7K | — | — | 2.57M | 393.8K | 3.0K | 3.46M | 74.34% | ↗ |
| 12 | 2020 | John McDonough, Former President and Chief Executive Officer | 72.9K | — | 75.0K | — | — | 1.02M | 1.17M | 6.41% | ↗ |
| 13 | 2020 | Anthony Pare, Chief Commercial Officer | 325.0K | — | 20.7K | 159.8K | 185.3K | 3.0K | 693.8K | 26.02% | ↗ |
| 14 | 2020 | Alec Barclay, SVP and Chief Operations Officer | 340.0K | — | 25.7K | 38.6K | 234.6K | 952.00 | 639.8K | 10.05% | ↗ |
| 15 | 2020 | Alec Barclay, Chief Operations Officer | 340.0K | — | 25.7K | 38.6K | 234.6K | 952.00 | 639.8K | 10.05% | ↗ |
| 16 | 2020 | Michael Gibbs, SVP and General Counsel | 340.0K | — | 19.5K | 29.7K | 178.5K | 3.0K | 570.6K | 8.61% | ↗ |
| 17 | 2019 | John McDonough, Former President and Chief Executive Officer | 550.0K | — | 372.0K | 478.7K | 233.8K | 3.0K | 1.64M | 51.95% | ↗ |
| 18 | 2019 | John McDonough, President and Chief Executive Officer | 550.0K | — | 372.0K | 478.7K | 233.8K | 3.0K | 1.64M | 51.95% | ↗ |
| 19 | 2019 | Alec Barclay, Senior Vice President, Operations | 337.5K | 35.0K | 111.6K | 348.8K | 102.0K | 2.9K | 937.8K | 49.10% | ↗ |
| 20 | 2019 | Alec Barclay, Chief Operations Officer | 337.5K | 35.0K | 111.6K | 348.8K | 102.0K | 2.9K | 937.8K | 49.10% | ↗ |
| 21 | 2019 | Thomas J. Lowery, Chief Scientific Officer | 362.3K | — | 111.6K | 246.2K | 108.7K | 3.0K | 831.8K | 43.02% | ↗ |
| 22 | 2018 | John McDonough, President and Chief Executive Officer | 497.9K | 31.3K | 2.23M | 951.5K | 309.4K | 3.0K | 4.02M | 79.08% | ↗ |
| 23 | 2018 | John Sprague, Chief Financial Officer | 323.5K | — | 336.6K | 713.6K | 120.3K | 3.0K | 1.50M | 70.15% | ↗ |
| 24 | 2018 | Thomas J. Lowery, Chief Scientific Officer | 360.2K | — | 579.1K | 285.5K | 135.8K | 3.0K | 1.36M | 63.40% | ↗ |
| 25 | 2017 | John McDonough, President and Chief Executive Officer | 425.0K | — | 283.5K | 332.9K | 280.5K | 3.0K | 1.32M | 46.52% | ↗ |
| 26 | 2017 | Darlene Deptula-Hicks, former Chief Financial Officer | 227.0K | — | — | — | 483.3K | — | 710.3K | 0.00% | ↗ |
| 27 | 2017 | Thomas J. Lowery, Chief Scientific Officer | 347.5K | — | 99.2K | 116.5K | 138.6K | 3.0K | 704.8K | 30.61% | ↗ |
| 28 | 2016 | John McDonough, President and Chief Executive Officer | 425.0K | — | 552.9K | 1.01M | 159.4K | 3.0K | 2.15M | 72.69% | ↗ |
| 29 | 2016 | Thomas J. Lowery, Chief Scientific Officer | 334.2K | — | 60.0K | 174.0K | 445.6K | 3.0K | 1.02M | 23.00% | ↗ |
| 30 | 2016 | Shawn P. Lynch, former Chief Financial Officer | 187.8K | — | — | 727.5K | — | — | 915.2K | 79.48% | ↗ |
| 31 | 2015 | John McDonough, President and Chief Executive Officer | 425.0K | — | — | 1.43M | 204.0K | — | 2.06M | 69.43% | ↗ |
| 32 | 2015 | Maurice Castonguay, Chief Financial Officer | 121.9K | — | — | 1.09M | 25.0K | — | 1.24M | 88.12% | ↗ |
| 33 | 2015 | David Harding, Chief Commercial Officer | 59.8K | — | — | 891.0K | 23.3K | — | 974.1K | 91.47% | ↗ |
| 34 | 2014 | John McDonough President and Chief Executive Officer | 380.4K | — | — | 599.4K | 265.6K | — | 1.25M | 48.13% | ↗ |
| 35 | 2014 | John McDonough, President and Chief Executive Officer | 380.4K | — | — | 599.4K | 265.6K | — | 1.25M | 48.13% | ↗ |
| 36 | 2014 | Michael A. Pfaller, M.D. Chief Medical Officer | 228.4K | — | — | 759.0K | 110.0K | — | 1.10M | 69.17% | ↗ |
| 37 | 2014 | Thomas J. Lowery, Ph.D. Chief Scientific Officer | 274.3K | — | — | 258.7K | 162.5K | — | 695.5K | 37.20% | ↗ |
| 38 | 2013 | John McDonough President and Chief Executive Officer | 350.0K | — | — | 310.9K | 66.0K | — | 726.9K | 42.77% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brett A. Giffin | Chief Commercial Officer | — | male |
| Craig R. Jalbert CIRA | Chief Executive Officer, President, Corporate Treasurer, Corporate Secretary & Director | — | male |
| Kelley J. Morgan | Chief People Officer | — | female |
| Roger Smith | Senior Vice President of Science Research & Development | — | — |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TTOO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
